Publications by authors named "M J Verbeek"
Parkinson's disease (PD) is a neurodegenerative disorder predominantly known for its motor symptoms such as bradykinesia, rigidity and tremor, but the disorder is also increasingly recognized for its association with impaired gastrointestinal function. The composition of the gut microbiome is known to be different in PD compared with healthy individuals. One of the bacterial families with increased abundance in people with PD is .
View Article and Find Full Text PDFWhether patients with acute myeloid leukemia (AML) harboring Nucleophosmin mutations (NPM1mut) with measurable residual disease (MRD) should undergo allogeneic stem cell transplantation (alloSCT) in complete remission (CR) remains subject of debate. This study aimed to assess whether the presence of bone marrow (BM) NPM1mut MRD, detected using a RT-qPCR assay with a sensitivity of 10-5, could influence the benefit derived from alloSCT. Data from four German transplantation centers were analyzed including 174 AML NPM1mut patients who underwent a first alloSCT between 2011-2022.
View Article and Find Full Text PDFArticle Synopsis
- Despite improvements in targeted therapy for Acute Myeloid Leukemia (AML), the prognosis remains poor, particularly for patients with relapsed or refractory disease.
- Allogeneic hematopoietic stem cell transplantation (alloSCT) is the main curative option for high-risk patients, but the best conditioning approach is still uncertain for those who are chemotherapy-refractory.
- A study on seven AML patients who received CXCR4-directed endoradiotherapy (ERT) combined with total body irradiation and chemotherapy prior to alloSCT showed promising outcomes, with 6 out of 7 patients achieving response and successful engraftment, offering insights into a potentially effective treatment strategy for advanced cases.
Article Synopsis
- Healthcare systems are significant contributors to CO emissions, making up 7% of emissions in the Netherlands, and evaluating treatments like SBRT and VATS can help reduce their climate impact.
- A life cycle assessment (LCA) was used to compare the carbon emissions of VATS and SBRT for treating Non-Small Cell Lung Cancer, considering patient travel, energy use, and medical supplies.
- Results showed VATS generates about 547 kg CO equivalent while SBRT contributes 172 kg CO equivalent, with energy consumption being the largest factor for both treatments; opportunities exist to reduce emissions by implementing strategies like fast-track recovery and improved treatment efficiencies.